Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug 12:13:89.
doi: 10.1186/1472-6947-13-89.

Influence of patient characteristics on perceived risks and willingness to take a proposed anti-rheumatic drug

Richard W Martin  1 , Kelsey McCallops, Andrew J Head, Aaron T Eggebeen, James D Birmingham, Donald J Tellinghuisen
Affiliations

Influence of patient characteristics on perceived risks and willingness to take a proposed anti-rheumatic drug

Richard W Martin et al. BMC Med Inform Decis Mak. .

Abstract

Background: The causes of the underutilization of disease modifying anti-rheumatic drugs (DMARDS) for rheumatoid arthritis (RA) are not fully known, but may in part, relate to individual patient factors including risk perception. Our objective was to identify the determinants of risk perception (RP) in RA patients and predictors of their willingness to take a proposed DMARD (DMARD willingness).

Methods: A cross-sectional mail survey of RA patients in a community rheumatology practice. Patients were presented a hypothetical decision scenario where they were asked to consider switching DMARDs. They evaluated how risky the proposed medication was and how likely they would be to take it.

Results: The completed sample included 1009 RA patients. The overall survey response rate was 71%.

Patient characteristics: age 61.6 years (range 18-93), 75% female, minority 6.5%, low or marginal health literacy 8.8%, depression 15.0%, duration RA 13.1 years (range 0.5 - 68). Regression models demonstrated that health literacy, independent of low educational achievement or other demographic (including race), was a common predictor of both RP and DMARD willingness. There was partial mediation of the effects of HL on DMARD willingness through RP. Depression and happiness had no significant effect on RP or DMARD willingness. RP was influenced by negative RA disease and treatment experience, while DMARD willingness was affected mainly by perceived disease control.

Conclusions: Risk aversion may be the result of potentially recognizable and correctable cognitive defect. Heightened clinician awareness, formal screening for low health literacy or cognitive impairment in high-risk populations, may identify patients could benefit from additional decision support.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mediation model.
See this image and copyright information in PMC

References

    1. Kazi S, Tillman M, Miller AS. The Physician Quality Reporting Initiative now includes rheumatoid arthritis measures group. Rheumatologist. 2009.
    1. Haraoui B, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Codreanu C, Da Silva JP, de Wit M, Dougados M, Durez P. et al.Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. Annals Rheum Dis. 2011;70(11):1999–2002. doi: 10.1136/ard.2011.154179. - DOI - PMC - PubMed
    1. Schoels M, Smolen JS. Treating rheumatoid arthritis to target: Evidence-based recommendations for enhanced disease management. Rheum Dis Clin North Am. 2012;8(1):1–2. - PubMed
    1. Schmajuk G, Trivedi AN, Solomon DH, Yelin E, Trupin L, Chakravarty EF, Yazdany J. Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA. 2011;305(5):480–486. doi: 10.1001/jama.2011.67. - DOI - PMC - PubMed
    1. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL. et al.A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343(22):1586–1593. doi: 10.1056/NEJM200011303432201. - DOI - PubMed

Publication types

MeSH terms

Substances